Last data update: Sep 16, 2024. (Total: 47680 publications since 2009)
Records 1-1 (of 1 Records) |
Query Trace: Markowitz LA [original query] |
---|
Provider attitudes toward HPV vaccine for males
Liddon N , Dunne E , Markowitz LA . J Adolesc Health 2010 47 (1) 1-2 Two prophylactic human papillomavirus (HPV) vaccines licensed by the U.S. Food and Drug Administration (FDA) have great potential to prevent HPV-associated diseases and cancers. In 2006, a quadrivalent vaccine that protects against four HPV types associated with most cases of genital warts and cervical cancers and in 2009 a bivalent vaccine that protects against two types associated with most cases of cervical cancer were licensed. The Advisory Committee on Immunization Practices (ACIP) recommends either vaccine for routine vaccination of 11- or 12-year-old female adolescents and catch-up vaccination of females through age 26 years. The quadrivalent HPV vaccine was recently licensed for use in males aged 9 through 26 years; ACIP did not recommend that the vaccine be used for routine use but that it may be given to males aged 9 through 26 years to reduce their likelihood of acquiring genital warts. Although HPV vaccine for males is not routinely recommended, it can still be covered by the Vaccines for Children Program. | For any vaccine, implementation is affected by attitudes and acceptance of the general public, parents, and providers. Studies show that the most influential factor in vaccination decisions is provider recommendation [1], [2], [3]. Most previous research on attitudes and acceptability for HPV vaccine has focused on vaccination of females; there has been less research related to males. The study in this issue by Weiss et al [4] provides valuable insight about providers' attitudes toward vaccinating males. Although not generalizable to pediatricians and family physicians as a whole, it does provide information on those already stocking and providing vaccine to females and who may consider providing vaccine to males. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Sep 16, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure